Who
Ryan J. Watts
President and CEO
Company insider
Files Form 4 as: President and CEO, Denali Therapeutics.
In numbers
- Trades disclosed
- 185
- Buys
- 0
- Sells
- 68
- Bought
- $0
- Sold
- $41.8M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 12 Dec 2017
- Last trade
- 12 Aug 2026
- Last filed
- 14 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 Aug 2026filed 14 Aug 2026 | DNLI Denali TherapeuticsBiotechnology | SEC FORM 4 Code G | —32,220 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | DNLI Denali TherapeuticsBiotechnology | SEC FORM 4 Code G | —32,220 at $0.00 | filing |
| 6 Jan 2026filed 8 Jan 2026 | DNLI Denali TherapeuticsBiotechnology | SEC FORM 4 Sold | $581K35,198 at $16.50 | filing |
| 6 Jan 2026filed 8 Jan 2026 | DNLI Denali TherapeuticsBiotechnology | SEC FORM 4 Sold | $581K35,198 at $16.50 | filing |
| 3 Jan 2026filed 5 Jan 2026 | DNLI Denali TherapeuticsBiotechnology | SEC FORM 4 Code A | —78,960 at $0.00 | filing |
| 3 Jan 2026filed 5 Jan 2026 | DNLI Denali Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —236,880 at $0.00 | filing |
| 3 Jan 2026filed 5 Jan 2026 | DNLI Denali Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —236,880 at $0.00 | filing |
| 3 Jan 2026filed 5 Jan 2026 | DNLI Denali TherapeuticsBiotechnology | SEC FORM 4 Code A | —78,960 at $0.00 | filing |
| 3 Sep 2025filed 5 Sep 2025 | DNLI Denali TherapeuticsBiotechnology | SEC FORM 4 Code G | —50,000 at $0.00 | filing |
| 9 Jul 2025filed 11 Jul 2025 | DNLI Denali Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —455,282 at $0.00 | filing |
| 9 Jul 2025filed 11 Jul 2025 | DNLI Denali Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —40,000 at $0.00 | filing |
| 9 Jul 2025filed 11 Jul 2025 | DNLI Denali TherapeuticsBiotechnology | SEC FORM 4 Code M | $310K455,282 at $0.68 | filing |
| 9 Jul 2025filed 11 Jul 2025 | DNLI Denali TherapeuticsBiotechnology | SEC FORM 4 Code M | $211K40,000 at $5.28 | filing |
| 9 Jul 2025filed 11 Jul 2025 | DNLI Denali TherapeuticsBiotechnology | SEC FORM 4 Sold | $7.4M495,282 at $15.00 | filing |
| 7 Jan 2025filed 8 Jan 2025 | DNLI Denali TherapeuticsBiotechnology | SEC FORM 4 Sold | $159K7,650 at $20.81 | filing |
| 6 Jan 2025filed 8 Jan 2025 | DNLI Denali TherapeuticsBiotechnology | SEC FORM 4 Sold | $592K29,266 at $20.22 | filing |
| 3 Jan 2025filed 7 Jan 2025 | DNLI Denali Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —162,540 at $0.00 | filing |
| 3 Jan 2025filed 7 Jan 2025 | DNLI Denali TherapeuticsBiotechnology | SEC FORM 4 Code A | —54,180 at $0.00 | filing |
| 18 Oct 2024filed 22 Oct 2024 | DNLI Denali Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —40,000 at $0.00 | filing |
| 18 Oct 2024filed 22 Oct 2024 | DNLI Denali TherapeuticsBiotechnology | SEC FORM 4 Code M | $27K40,000 at $0.68 | filing |
News
Denali Therapeutics (NASDAQ:DNLI) vs. Century Therapeutics (NASDAQ:IPSC) Head-To-Head ContrastDNLI · themarketsdaily.com · 19 Oct 2026Denali Therapeutics (NASDAQ:DNLI) and Absci (NASDAQ:ABSI) Head to Head ComparisonDNLI · tickerreport.com · 11 Oct 2026
0 headlines in the last 90 days name Ryan J. Watts; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.